MonaLisa PH.
Polynucleotide combined with cross-stabilised hyaluronic acid — the topical skin-needling serum from Seoul, formulated for the patient who wants both hydration and long-term skin quality.
Topical skin-needling serum, manufactured in Seoul by GENOSS, distributed in Australia by Power to Practice. Refer to the IFU for full handling and use guidance.
Listed on the Australian Register of Therapeutic Goods.
Direct supply from manufacturer to your clinic.
Local training, mentorship and same-day response.
Two actives, working together.
Two complementary actives
Long-chain polynucleotide paired with cross-stabilised hyaluronic acid — built for clinics already running needling protocols who want a hybrid serum on the menu.
Hydration that holds
The HA component delivers visible hydration on day one. The PN component supports the skin's longer-term quality across the protocol.
Glow you can see
Designed for the luminosity patients describe as glass-skin — the K-clinic look, in your own treatment room.
Pairs with PN 30
Run PH as a standalone hybrid on the menu, or alternate with PN 30 across a protocol to give patients a clear progression they can feel.
At a glance.
- Product
- MonaLisa PH
- Active System
- Polynucleotide + cross-linked HA
- Format
- Pre-filled syringe · 2.0 mL
- Application
- Topical · skin-needling adjunct
- Protocol
- Custom per patient · typically 2–4 sessions
- Storage
- 2–25 °C, away from sunlight
- Manufacturer
- GENOSS Co., Ltd. — Seoul, South Korea